




Daniel Jünemann (Autor)

# **Analytics of dissolution testing of products containing nanosized drugs with a view to predicting plasma profiles**



<https://cuvillier.de/de/shop/publications/115>

Copyright:

Cuvillier Verlag, Inhaberin Annette Jentzsch-Cuvillier, Nonnenstieg 8, 37075 Göttingen, Germany

Telefon: +49 (0)551 54724-0, E-Mail: [info@cuvillier.de](mailto:info@cuvillier.de), Website: <https://cuvillier.de>



## Table of contents:

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	<i>Oral bioavailability</i> .....	1
1.2	<i>Factors limiting oral bioavailability</i> .....	2
1.3	<i>Solubility and drug dissolution</i> .....	3
1.4	<i>The biopharmaceutics classification system</i> .....	5
1.5	<i>Formulation of poorly soluble substances</i> .....	8
1.6	<i>Particle size reduction in pharmaceutical technology</i> .....	13
1.6.1	<i>Particle size reduction</i> .....	14
1.6.2	<i>Dry milling methods</i> .....	16
1.6.3	<i>Wet milling methods</i> .....	17
1.6.4	<i>Comparison of dry and wet milling techniques</i> .....	17
1.6.5	<i>Combining micronization with other techniques</i> .....	18
1.7	<i>Rationale for nanonization of drug particles</i> .....	19
1.8	<i>Preparation of nanosized drug particles</i> .....	20
1.8.1	<i>Wet-milling methods (bead mills)</i> .....	21
1.8.2	<i>High pressure homogenization</i> .....	23
1.8.3	<i>Commercialized nanosized drugs</i> .....	24
1.8.4	<i>Increase of bioavailability by nanonization</i> .....	25
1.8.5	<i>The lack of food effects using nanosized APIs</i> .....	27
1.8.6	<i>Improvement of bioavailability for drugs with an absorption window</i> .....	28
1.9	<i>Sample preparation and analysis in dissolution testing</i> .....	29
1.9.1	<i>HPLC-UV</i> .....	30
1.9.1.1	<i>The use of syringe filter</i> .....	30
1.9.1.2	<i>Centrifugal filter devices</i> .....	31
1.9.1.3	<i>Dialysis methods</i> .....	31
1.9.1.4	<i>Microdialysis</i> .....	32
1.9.2	<i>Fiber optics</i> .....	32
1.9.3	<i>Turbidity measurement</i> .....	34
1.9.4	<i>ResoScan</i> .....	35
1.9.5	<i>Asymmetrical flow - field-flow fractionation</i> .....	35
1.9.6	<i>Ion-selective electrode</i> .....	37
<b>2</b>	<b>Aims of thesis</b>	<b>39</b>
2.1	<i>Evaluation of the use of an ion-selective electrode system in biorelevant dissolution testing using diphenhydramine HCl as model drug</i> .....	39



2.2	<i>Evaluation of the ion-selective electrode as potential tool for analysis of supersaturated systems</i>	39
2.3	<i>Evaluation of analytical methods in dissolution testing of nanosized fenofibrate</i>	40
2.4	<i>Establishment of an in vitro - in vivo - correlation for a nanosized drug using an in silico simulation approach</i>	40
<b>3</b>	<b>Materials and Methods</b>	<b>41</b>
3.1	<i>Materials</i>	41
3.1.1	<i>Chemicals</i>	41
3.1.2	<i>Model substance diphenhydramine HCl</i>	43
3.1.3	<i>Model substance fenofibrate</i>	44
3.2	<i>Methods</i>	46
3.2.1	<i>Case example of particle size reduction: fenofibrate</i>	46
3.2.2	<i>Dissolution studies</i>	48
3.2.3	<i>Composition of dissolution media</i>	49
3.2.4	<i>Syringe filters</i>	50
3.2.5	<i>Microdialysis system</i>	51
3.2.6	<i>Centrifugal filter devices</i>	51
3.2.7	<i>High performance liquid chromatography (HPLC-UV) used for assays</i>	52
3.2.8	<i>ResoScan system</i>	53
3.2.9	<i>Analyses of in vitro data</i>	54
3.2.9.1	<i>Model independent <math>f_1</math>- and <math>f_2</math>- factor calculation</i>	54
3.3	<i>Special methods for diphenhydramine HCl</i>	54
3.3.1	<i>Filter adsorption studies for diphenhydramine HCl</i>	54
3.3.2	<i>Dynamic light scattering</i>	55
3.3.3	<i>The ion-selective electrode</i>	55
3.3.4	<i>Calibration of the ion-selective electrode for diphenhydramine HCl</i>	56
3.3.5	<i>Dissolution testing</i>	57
3.3.6	<i>Endpoint calibration via ISE (method A)</i>	57
3.3.7	<i>Endpoint calibration via HPLC-UV (method B)</i>	58
3.3.8	<i>Adaption of Method B for measurement of poorly soluble substances</i>	58
3.3.9	<i>Analysis of significance using ANOVA</i>	58
3.4	<i>Special methods for fenofibrate</i>	59
3.4.1	<i>Filter adsorption studies for fenofibrate</i>	59
3.4.2	<i>Analysis of in vivo pharmacokinetic data</i>	59
3.4.3	<i>Computer simulation of fenofibric acid plasma profiles</i>	60
3.4.3.1	<i>The STELLA<sup>®</sup> model</i>	60



3.4.3.2	Calculation of z-value.....	66
3.4.3.3	Adaption of original model for permeability restrictions .....	67
3.4.4	Comparison of simulated plasma profiles to in vivo data.....	68
3.4.5	Sensitivity analyses.....	69
<b>4</b>	<b>Results and discussion</b>	<b>70</b>
4.1	Discussion of methods evaluated for in situ measurement of the analyte in the dissolution test .....	70
4.2	ResoScan.....	71
4.3	Microdialysis.....	72
4.4	Centrifugal filter devices .....	73
4.1	Ion-selective electrode .....	75
4.1.1	Filter adsorption studies.....	75
4.1.2	FaSSGF.....	75
4.1.3	FaSSIF .....	77
4.1.4	FaSSIF-V2.....	82
4.1.5	FeSSGF.....	84
4.1.6	FeSSIF / FeSSIF-V2.....	86
4.1.7	Evaluation of potential use of the ISE for nanosized drugs .....	88
4.2	Fenofibrate .....	91
4.2.1	Filter adsorption studies.....	91
4.2.2	Solubility studies.....	94
4.2.3	Dissolution in FaSSIF and FeSSIF using various filter pore sizes .....	95
4.3	Theoretical increase of dissolution rate by particle size reduction.....	99
4.4	Comparison of dissolution rate in theory and in practice .....	102
4.5	Evaluation of the STELLA <sup>®</sup> software to generate simulated plasma profiles .....	103
4.6	Discussion of the conventional approach vs. a new method for rapidly dissolving compounds.....	105
4.7	Calculation of z-values .....	109
4.8	Simulated plasma profiles of fenofibric acid Model A .....	110
4.8.1	Sensitivity analyses model A .....	111
4.8.1.1	Influence of gastric emptying rate.....	111
4.8.1.2	Influence of gastric dissolution rate .....	114
4.8.1.3	Influence of intestinal dissolution rate.....	116
4.9	Simulated plasma profiles of fenofibric acid model B.....	118
4.9.1	Sensitivity analyses Model B .....	119
4.9.1.1	Influence of intestinal dissolution in the fasted state.....	120



4.9.1.2	<i>Influence of gastric emptying rate in the fed state.....</i>	<i>121</i>
4.9.1.3	<i>Influence of permeation rate across the intestinal mucosa.....</i>	<i>122</i>
4.9.2	<i>Discussion of STELLA<sup>®</sup> software .....</i>	<i>123</i>
4.9.2.1	<i>Possible applications using the presented model in STELLA<sup>®</sup> .....</i>	<i>124</i>
4.9.2.2	<i>Limitations of the STELLA<sup>®</sup> model .....</i>	<i>125</i>
<b>5</b>	<b>General discussion of thesis</b>	<b>126</b>
<b>6</b>	<b>Outlook</b>	<b>133</b>
6.1	<i>Studies regarding the ISE .....</i>	<i>133</i>
6.2	<i>Filter adsorption testing.....</i>	<i>133</i>
6.3	<i>Establishment of an in vitro - in vivo - correlation for a nanosized drug.....</i>	<i>134</i>
<b>7</b>	<b>Summary</b>	<b>135</b>
<b>8</b>	<b>Appendix</b>	<b>141</b>
<b>9</b>	<b>References</b>	<b>166</b>
<b>10</b>	<b>Summary (German)</b>	<b>173</b>
<b>11</b>	<b>Curriculum vitae</b>	<b>179</b>